- Home
- NIU vs MREO Comparison
NIU vs MREO Comparison
Compare NIU & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- MREO
- Stock Information
- Founded
- NIU 2014
- MREO 2015
- Country
- NIU China
- MREO United Kingdom
- Employees
- NIU N/A
- MREO N/A
- Industry
- NIU Auto Manufacturing
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- NIU Consumer Discretionary
- MREO Health Care
- Exchange
- NIU Nasdaq
- MREO Nasdaq
- Market Cap
- NIU 275.6M
- MREO 326.1M
- IPO Year
- NIU 2018
- MREO N/A
- Fundamental
- Price
- NIU $5.43
- MREO $1.97
- Analyst Decision
- NIU
- MREO Strong Buy
- Analyst Count
- NIU 0
- MREO 5
- Target Price
- NIU N/A
- MREO $7.40
- AVG Volume (30 Days)
- NIU 840.9K
- MREO 1.3M
- Earning Date
- NIU 11-17-2025
- MREO 11-11-2025
- Dividend Yield
- NIU N/A
- MREO N/A
- EPS Growth
- NIU N/A
- MREO N/A
- EPS
- NIU N/A
- MREO N/A
- Revenue
- NIU $527,760,629.00
- MREO $500,000.00
- Revenue This Year
- NIU $41.32
- MREO N/A
- Revenue Next Year
- NIU $24.38
- MREO $72.16
- P/E Ratio
- NIU N/A
- MREO N/A
- Revenue Growth
- NIU 32.62
- MREO N/A
- 52 Week Low
- NIU $1.66
- MREO $1.47
- 52 Week High
- NIU $5.67
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- NIU 67.57
- MREO 57.79
- Support Level
- NIU $4.42
- MREO $1.94
- Resistance Level
- NIU $5.67
- MREO $2.12
- Average True Range (ATR)
- NIU 0.33
- MREO 0.11
- MACD
- NIU 0.09
- MREO 0.02
- Stochastic Oscillator
- NIU 85.21
- MREO 62.65
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).